Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 20/20 | 0.71 |
| ▸ | CDK2 | P24941 | 19/20 | 0.71 |
| ▸ | KDR | P35968 | 15/20 | 0.71 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CDK7 | P50613 | 2/20 | 0.46 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNH | P51946 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367840 | 1.00 | CDK1 (0.71) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14367844 | 0.88 | CDK1 (0.69) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14367843 | 0.85 | CDK1 (0.71) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14367842 | 0.85 | CDK1 (0.70) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL5151974 | 0.84 | CDK1 (0.52) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14367841 | 0.84 | CDK1 (0.52) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL13442831 | 0.83 | CDK1 (1.00) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14367846 | 0.83 | CDK1 (0.71) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL14367845 | 0.83 | CDK1 (0.52) | CDK1CDK2KDRCCNB1CCNE1 | |
| SCHEMBL5156815 | 0.83 | CDK1 (0.71) | CDK1CDK2KDRCCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288547-B2 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2007-10-30 | — | — | US | disclosed |
| EP-1483260-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | Schering Aktiengesellschaft (DE) | 2004-12-08 | — | — | EP | disclosed |
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2004-04-01 | — | — | US | disclosed |
| WO-2003076437-A1 | CDK INHIBITING 2-HETEROARYL PYRIMIDINE, THE PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063737-A1 | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents | CDK2, CDK6, CDKL2 | CDK1 7/4885CDK2 1/4885KDR 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.